Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
E-pub ahead of print

Inactivated genotype 1a, 2a and 3a HCV vaccine candidates induced broadly neutralising antibodies in mice

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. HCV genome-wide analysis for development of efficient culture systems and unravelling of antiviral resistance in genotype 4

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Vaccines against hepatitis C: a travel into neutralisation space

    Publikation: Bidrag til tidsskriftKommentar/debatForskningpeer review

  1. Two-component vaccine consisting of virus-like particles displaying hepatitis C virus envelope protein 2 oligomers

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Neutralization and receptor use of infectious culture-derived rat hepacivirus as a model for HCV

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. An Adaptable Platform for in-house Hepatitis C Serology

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Protection against SARS-CoV-2 transmission by a parenteral prime-Intranasal boost vaccine strategy

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

OBJECTIVE: A prophylactic vaccine is needed to control the HCV epidemic, with genotypes 1-3 causing >80% of worldwide infections. Vaccine development is hampered by HCV heterogeneity, viral escape including protection of conserved neutralising epitopes and suboptimal efficacy of HCV cell culture systems. We developed cell culture-based inactivated genotype 1-3 HCV vaccine candidates to present natively folded envelope proteins to elicit neutralising antibodies.

DESIGN: High-yield genotype 1a, 2a and 3a HCV were developed by serial passage of TNcc, J6cc and DBN3acc in Huh7.5 cells and engineering of acquired mutations detected by next-generation sequencing. Neutralising epitope exposure was determined in cell-based neutralisation assays using human monoclonal antibodies AR3A and AR4A, and polyclonal antibody C211. BALB/c mice were immunised with processed and inactivated genotype 1a, 2a or 3a viruses using AddaVax, a homologue of the licenced adjuvant MF-59. Purified mouse and patient serum IgG were assayed for neutralisation capacity; mouse IgG and immune-sera were assayed for E1/E2 binding.

RESULTS: Compared with the original viruses, high-yield viruses had up to ~1000 fold increased infectivity titres (peak titres: 6-7 log10 focus-forming units (FFU)/mL) and up to ~2470 fold increased exposure of conserved neutralising epitopes. Vaccine-induced IgG broadly neutralised genotype 1-6 HCV (EC50: 30-193 µg/mL; mean 71 µg/mL), compared favourably with IgG from chronically infected patients, and bound genotype 1-3 E1/E2; immune-sera endpoint titres reached up to 32 000.

CONCLUSION: High-yield genotype 1-3 HCV could be developed as basis for inactivated vaccine candidates inducing broadly neutralising antibodies in mice supporting further preclinical development.

OriginalsprogEngelsk
Artikelnummer326323
TidsskriftGut
Sider (fra-til)1-13
Antal sider13
ISSN0017-5749
DOI
StatusE-pub ahead of print - 2 aug. 2022

Bibliografisk note

© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

ID: 79863416